We are live on ! Find out more
SCM

Silverarc Capital Management Portfolio holdings

AUM $962M
1-Year Est. Return 524.64%
This Fund
S&P 500
This Quarter Est. Return
+26.72%
1 Year Est. Return
+524.64%
3 Year Est. Return
+2,765.44%
5 Year Est. Return
+10,523.08%
10 Year Est. Return
–
AUM
$980M
AUM Growth
+$260M
Cap. Flow
+$316M
Cap. Flow %
32.2%
Top 10 Hldgs %
50.1%
Holding
93
New
25
Increased
16
Reduced
28
Closed
20

Top Buys

Rank Stock Value
1
ZBIO
Zenas BioPharma
ZBIO
+$25.5M
2
GLUE icon
Monte Rosa Therapeutics
GLUE
+$18.6M
3
ASND icon
Ascendis Pharma A/S
ASND
+$16.9M
4
RYTM icon
Rhythm Pharmaceuticals
RYTM
+$16.5M
5
IMNM icon
Immunome
IMNM
+$16.1M

Top Sells

Rank Stock Value
1
ABVX
Abivax
ABVX
+$14.2M
2
CGON icon
CG Oncology
CGON
+$11M
3
VRDN icon
Viridian Therapeutics
VRDN
+$10.8M
4
PFE icon
Pfizer
PFE
+$10.4M
5
AVTX icon
Avalo Therapeutics
AVTX
+$9.52M

Sector Composition

Rank Sector Weight
1 Healthcare 85.36%
2 Financials 1.25%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
CTMX icon
76
CytomX Therapeutics
CTMX
$730M
– –
-385,974
Closed -$1.64M
FDMT icon
77
4D Molecular Therapeutics
FDMT
$609M
– –
-100,000
Closed -$750K
GOSS icon
78
Gossamer Bio
GOSS
$83.3M
– –
-2,135,722
Closed -$6.62M
KALV
79
CALL
DELISTED
KalVista Pharmaceuticals
KALV
– –
-290,600
Closed -$4.69M
KYMR icon
80
Kymera Therapeutics
KYMR
$9.51B
– –
-34,589
Closed -$2.69M
LXEO icon
81
Lexeo Therapeutics
LXEO
$407M
– –
-617,608
Closed -$6.13M
MLYS icon
82
Mineralys Therapeutics
MLYS
$2.31B
– –
-94,983
Closed -$3.45M
OLMA icon
83
Olema Pharmaceuticals
OLMA
$920M
– –
-206,280
Closed -$5.16M
PALI icon
84
Palisade Bio
PALI
$375M
– –
-102,108
Closed -$240K
PFE icon
85
Pfizer
PFE
$153B
– –
-419,134
Closed -$10.4M
QURE icon
86
uniQure
QURE
$3.26B
– –
-126,047
Closed -$2.55M
RARE icon
87
CALL
Ultragenyx Pharmaceutical
RARE
$2.6B
– –
-110,000
Closed -$2.53M
RLAY icon
88
Relay Therapeutics
RLAY
$4.37B
– –
-398,167
Closed -$3.37M
SLNO
89
DELISTED
Soleno Therapeutics
SLNO
– –
-117,485
Closed -$5.44M
TARS icon
90
Tarsus Pharmaceuticals
TARS
$3.02B
– –
-36,124
Closed -$2.96M
VRDN icon
91
Viridian Therapeutics
VRDN
$2.49B
– –
-348,569
Closed -$10.8M
XFOR icon
92
X4 Pharmaceuticals
XFOR
$425M
– –
-357,387
Closed -$1.43M
RAPP
93
Rapport Therapeutics
RAPP
$2.27B
– –
-9,659
Closed -$293K
1 2 3
4

Similar funds

MK
MASTERINVEST Kapitalanlage Vienna $962M AUM 27.59% 1-Year Est. Return
QIM
Quantitative Investment Management Charlottesville, Virginia $963M AUM 12.95% 1-Year Est. Return
TC
TwinBeech Capital Purchase, New York $965M AUM 0.23% 1-Year Est. Return
GHC
Graham Holdings Company Arlington, Virginia $967M AUM 15.12% 1-Year Est. Return
WAM
WNY Asset Management Williamsville, New York $967M AUM
LOAMU
Lombard Odier Asset Management (USA) New York $957M AUM 35.8% 1-Year Est. Return
PHP
Parkman Healthcare Partners Stamford, Connecticut $970M AUM 79.46% 1-Year Est. Return
PO
Paradigm Operations San Francisco, California $954M AUM 20.29% 1-Year Est. Return

Silverarc Capital Management's Q1 2026 Portfolio in Review

As of Q1 2026, Silverarc Capital Management held 93 positions worth $980M, up 36% from $720M the previous quarter. Its ten largest holdings account for 50% of the portfolio.

Silverarc Capital Management deployed $316M of net new capital in Q1 2026, opening 25 new positions and adding to 16 existing holdings. Its largest new stake was Zenas BioPharma: 1,135,935 shares worth $22.2M.

By sector, the portfolio is most concentrated in Healthcare at 85% of assets, down from 96% a quarter earlier, followed by Financials.

On the sell side, the largest reduction was Abivax, an estimated $14.2M trimmed.

  • Silverarc Capital Management's largest Q1 2026 buy was Zenas BioPharma: 1,135,935 shares worth $22.2M.
  • Silverarc Capital Management added most to Monte Rosa Therapeutics in Q1 2026, an estimated $18.6M increase.
  • Silverarc Capital Management's biggest Q1 2026 reduction was Abivax, cutting an estimated $14.2M.
  • Silverarc Capital Management fully exited Viridian Therapeutics in Q1 2026, selling an estimated $10.8M.
  • Silverarc Capital Management's ten largest holdings make up 50% of its $980M portfolio in Q1 2026.
  • Silverarc Capital Management opened 25 new positions and closed 20 in Q1 2026.
  • Silverarc Capital Management's portfolio value rose 36% quarter-over-quarter to $980M.

Based on Silverarc Capital Management's 13F filing for Q1 2026, filed 14 May 2026.